241 related articles for article (PubMed ID: 32132421)
1. Office-Based Buprenorphine Treatment: Identifying Factors That Promote Retention in Opioid-Dependent Patients.
Noe SR; Keller T
J Addict Nurs; 2020; 31(1):23-29. PubMed ID: 32132421
[TBL] [Abstract][Full Text] [Related]
2. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
[TBL] [Abstract][Full Text] [Related]
3. Long-term retention in Office Based Opioid Treatment with buprenorphine.
Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
[TBL] [Abstract][Full Text] [Related]
4. Pain is not associated with worse office-based buprenorphine treatment outcomes.
Fox AD; Sohler NL; Starrels JL; Ning Y; Giovanniello A; Cunningham CO
Subst Abus; 2012; 33(4):361-5. PubMed ID: 22989279
[TBL] [Abstract][Full Text] [Related]
5. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
6. Supportive alternate site provision of buprenorphine: Overcoming barriers and improving patient outcomes.
Khan A; Khan Q; Kolb E
J Subst Abuse Treat; 2021 Apr; 123():108256. PubMed ID: 33612191
[TBL] [Abstract][Full Text] [Related]
7. Development of an integrated digital health intervention to promote engagement in and adherence to medication for opioid use disorder.
Langdon KJ; Ramsey S; Scherzer C; Carey K; Ranney ML; Rich J
Addict Sci Clin Pract; 2020 Apr; 15(1):16. PubMed ID: 32349790
[TBL] [Abstract][Full Text] [Related]
8. Adherence to buprenorphine: An analysis of prescription drug monitoring program data.
Pizzicato LN; Hom JK; Sun M; Johnson CC; Viner KM
Drug Alcohol Depend; 2020 Nov; 216():108317. PubMed ID: 33035714
[TBL] [Abstract][Full Text] [Related]
9. Primary care patient characteristics associated with completion of 6-month buprenorphine treatment.
Neumann AM; Blondell RD; Azadfard M; Nathan G; Homish GG
Addict Behav; 2013 Nov; 38(11):2724-8. PubMed ID: 23934003
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of Implementing Shared Medical Appointments (SMAs) for Office-Based Opioid Treatment With Buprenorphine: A Pilot Study.
Suzuki J; Zinser J; Klaiber B; Hannon M; Grassi H; Spinosa M; Ramirez A; Issa M; Chin Feman SP
Subst Abus; 2015; 36(2):166-9. PubMed ID: 25738320
[TBL] [Abstract][Full Text] [Related]
11. Association between opioid analgesic therapy and initiation of buprenorphine management: An analysis of prescription drug monitoring program data.
Alexandridis AA; Dasgupta N; Ringwalt CL; Rosamond WD; Chelminski PR; Marshall SW
PLoS One; 2020; 15(1):e0227350. PubMed ID: 31923197
[TBL] [Abstract][Full Text] [Related]
12. Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users.
Cunningham CO; Giovanniello A; Kunins HV; Roose RJ; Fox AD; Sohler NL
Am J Addict; 2013; 22(4):352-7. PubMed ID: 23795874
[TBL] [Abstract][Full Text] [Related]
13. The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice.
Wiegand TJ
J Med Toxicol; 2016 Mar; 12(1):64-70. PubMed ID: 26574020
[TBL] [Abstract][Full Text] [Related]
14. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
Manhapra A; Agbese E; Leslie DL; Rosenheck RA
Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
[TBL] [Abstract][Full Text] [Related]
15. Bridging waitlist delays with interim buprenorphine treatment: initial feasibility.
Sigmon SC; C Meyer A; Hruska B; Ochalek T; Rose G; Badger GJ; Brooklyn JR; Heil SH; Higgins ST; Moore BA; Schwartz RP
Addict Behav; 2015 Dec; 51():136-42. PubMed ID: 26256469
[TBL] [Abstract][Full Text] [Related]
16. Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review.
Feelemyer J; Des Jarlais D; Arasteh K; Abdul-Quader AS; Hagan H
Addiction; 2014 Jan; 109(1):20-32. PubMed ID: 23859638
[TBL] [Abstract][Full Text] [Related]
17. Group-based treatment of opioid use disorder with buprenorphine: A systematic review.
Sokol R; LaVertu AE; Morrill D; Albanese C; Schuman-Olivier Z
J Subst Abuse Treat; 2018 Jan; 84():78-87. PubMed ID: 29195596
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine Medication for Opioid Use Disorder: A Study of Factors Associated With Postpartum Treatment Retention.
Ray-Griffith S; Tharp E; Coker JL; Catlin D; Knight B; Stowe ZN
Am J Addict; 2021 Jan; 30(1):43-48. PubMed ID: 32673447
[TBL] [Abstract][Full Text] [Related]
19. A Comparison of Medication-Assisted Treatment Options for Opioid Addiction: A Review of the Literature.
Spayde-Baker A; Patek J
J Addict Nurs; 2023 Oct-Dec 01; 34(4):E189-E194. PubMed ID: 34224485
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
